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Abstract  
Insulin resistance underpins the link between obesity and most of its associated metabolic 
disorders including type 2 diabetes, fatty liver disease, dyslipidaemia and cardiovascular 
disease. Despite its importance and extensive scientific endeavour, its precise molecular 
pathogenesis remains unclear. Monogenic syndromes of extreme insulin resistance, whilst 
rare in themselves, can provide unique insights into the pathogenesis of human insulin 
resistance. Severe insulin resistance syndromes are broadly classified into three categories: 
lipodystrophies, primary insulin signalling defects or complex syndromes including severe 
insulin resistance. Genetically confirmed classification has facilitated the identification of 
robust diagnostic biochemical features accelerating accurate clinical diagnosis. Interestingly 
the biochemical features of lipodystrophies are far more closely aligned to what is seen in 
prevalent forms of insulin resistance than those of primary insulin signalling defects, 
suggesting that lipodystrophy could be a relevant model for common disease. This assertion 
is supported by genome-wide association data indicating that SNPs associated with fasting 
hyperinsulinemia and metabolic dyslipidaemia, are strongly associated with a subtle 
reduction in hip fat, suggesting that subtle forms of lipodystrophy are likely to be a 
significant contributor to prevalent insulin resistance. 
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Introduction 
Severe insulin resistance syndromes(SIRS) are a complex group of disorders with impaired  
cellular responsiveness to insulin manifesting as reduced biological activity to a given 
concentration of the hormone(1). The normal pancreatic response to insulin resistance(IR) is 
to increase beta cell insulin secretion(2). Insulin is measurable in plasma and a fasting or 
glucose stimulated level is often sufficient to make the diagnosis of IR(3). However, insulin is 
infrequently measured in clinical practice, and often only considered after an individual has 
presented with one of the hallmarks of chronic hyperinsulinemia. The first of these  are 
cutaneous manifestations of IR including acanthosis nigricans, a velvety hyperpigmented 
thickening of the skin and  acrochordan’s (skin tags) which are fibrous dermal benign tumours 
often localised to skin creases(4, 5). The purported pathogenesis relates to the cross reactivity 
of insulin with the IGF-1 receptor(6). Polycystic ovaries, menstrual irregularities and 
hyperandrogenism are prevalent in syndromes of severe IR and often constitute the primary 
clinical manifestation in women. Hyperinsulinemia has been implicated in the pathogenesis 
of PCOS (polycystic ovary syndrome); a notion supported by improvements in PCOS features 
in states of reversible hyperinsulinemia such as type B IR due to insulin receptor 
autoantibodies(7, 8). Another trait commonly observed in states of severe IR is altered 
glucose homeostasis. Impaired glucose tolerance and diabetes mellitus develop when the 
beta cell compensatory response to IR is insufficient to regulate glucose metabolism(9). This 
may reduce the diagnostic utility of insulin measurements.  
 
SIRS  are grouped into three categories 1. Disorders characterised by a primary impairment 
of  adipocyte energy storage with adverse secondary impact on glucose handling by muscle 
and liver (Lipodystrophies) 2. Primary insulin signalling defects; and 3. Complex syndromes 
associated with IR. In this review we will briefly discuss recent progress in genetically 
classifying these syndromes, how they can be distinguished phenotypically and how they 
inform mechanistic understanding of more prevalent IR.  
 
 
Severe Insulin Resistance Syndromes 
 
• The Lipodystrophies 
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White adipose tissue is critical for the efficient storage of excess energy as triglyceride (TG) in 
lipid droplets. Lipodystrophies are a heterogeneous group of rare disorders  characterised by 
a loss of adipose tissue and a depletion of lipid storage capacity(10, 11). The failure of this 
system places a demand on non-adipose sites, typically liver and muscle, to buffer excess 
circulating TG. The principle of adipose tissue expandability refers to the hypothesis that 
humans have a ‘limited capacity’ to increase the size and number of adipocytes(12, 13). In 
states of sustained positive energy balance, adipose tissue stores TG up to this threshold but 
once exceeded ectopic TG deposition occurs, and in turn results in impaired insulin action in 
target tissues like the liver and skeletal muscle(14).  
 
Lipodystrophies are classified according to the extent of adipose loss (generalised or partial) 
and the primary cause of the disorder (genetic or acquired). Congenital generalised 
lipodystrophies(CGL) represent the severe end of the spectrum with a near complete loss of 
subcutaneous adipose tissue  presenting from birth(15).  AGPAT2 and  BSCL2 were the earliest 
loci identified in Berardenelli-Seip syndromes with significant overlap between the  
phenotypes(16).  Owing to the degree of adipose failure seen in CGL secondary complications 
manifest in childhood where in addition to developing the hallmarks of IR those effected have 
dyslipidaemia and non-alcoholic fatty liver disease(NAFLD) with the potential for developing 
steatohepatitis, cirrhosis and hepatic failure. In contrast to CGL, familial partial 
lipodystrophies (FPLD) are heritable disorders with varying degrees of subcutaneous fat  loss, 
usually manifesting around puberty in girls and somewhat later in men. The best 
characterised subtypes include: 1) FPLD1 or Köbberling syndrome presenting with adipose 
tissue loss in the extremities but preserved or excess abdominal adiposity(17); 2) FPLD2, a 
monogenic disorder caused by LMNA mutations which in contrast to Köbberling  syndrome 
classically presents with reduced subcutaneous adipose tissues in the limbs, abdomen and 
torso with adipose tissue accumulation in the face, neck and labia majora in females(18); 3) 
FPLD3 due to mutations in PPARG has a pattern of fat loss similar to FPLD1 although severe 
labile hypertriglyceridemia and hypertension are more frequent in affected individuals(19, 
20). Metabolic complications vary depending on the extent of the lipodystrophic phenotype 
but NAFLD, IR, dyslipidaemia and secondary diabetes are common in all three. Recently a 
number of other genetic loci have been identified for both generalised and partial 
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lipodystrophy (table 1). In two very rare subtypes due to mutations in CIDEC and PLIN1, the 
mutant proteins are almost exclusively expressed in adipocytes where they are directly 
involved in TG storage within lipid droplets, providing proof-in-principle that primary defects 
in adipose lipid storage are sufficient to cause the metabolic syndrome(11). 
 
Acquired lipodystrophies have also been reported; not infrequently associated with other 
autoimmune disorders. Barraquer-Simons is well described as cephalocaudal fat loss, a 
deficiency in complement (C3), part of the innate immune response and 
mesangioproliferative glomerulonephritis(21). A metabolic phenotype is rarely seen in this 
condition, likely due to the sparing of gluteofemoral subcutaneous tissue (GSAT) depots 
which sequester excess TG. This finding is in contrast to the severity of metabolic disease 
observed in lipodystrophies where GSAT is depleted. Acquired generalised 
lipodystrophies(AGL) are very rare and may be idiopathic, associated with radiotherapy 
and/or drug exposure, or very rarely a cluster of conditions including haemolysis, hepatitis 
and low C4 complement levels(22). The precise pathophysiology of AGL has not been 
delineated though it is assumed to be autoimmune and the metabolic sequelae can be very 
severe(22, 23).  
 
 
• Insulin Receptor Signalling Defects 
 
Mutations in the INSR gene or a gene encoding a protein mediating its downstream signalling 
can cause severe IR. The most severe syndromes are associated with biallelic INSR mutations, 
namely Donohoe and Rabson-Mendenhall syndromes(24, 25). Both present after birth with 
failure to thrive, reduced muscle and adipose mass, and developmental delay. The ensuing 
hyperinsulinemia in the face of defective INSR function lead to the clinical manifestations of 
IR. Less deleterious, often heterozygous, mutations affecting the INSR may present with a 
milder, though still severe, phenotype manifesting post-pubertally; this presentation is often 
referred to as Type A IR(26). Type B IR differs physiologically from INSR mutations presenting 
acutely with features of severe IR due to the development of anti-insulin receptor antibodies. 
This condition is most often described in females of African ethnicity (27). Beyond the insulin 
receptor there is a complex cascade of intracellular proteins and kinases that if disrupted may 
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also manifest with an insulin resistant phenotype (table 1); collectively these disorders can 
be classified under the term ‘insulin receptoropathy’. 
 
The study of patients with lipodystrophies and insulin receptoropathies has led to the 
identification of distinct clinically useful differences between the phenotypes enabling 
stratification prior to genetic testing – these include: 
 
1. Dyslipidaemia and NAFLD are common complications of lipodystrophic syndromes 
and will almost certainly be present in patients who are insulin resistant at the time, 
whereas conditions of impaired proximal insulin receptor signalling are free of such 
metabolic derangement. The proposed mechanism relates to  an increase in de novo 
lipogenesis (DNL) and the TG rich very low density lipoprotein cholesterol (VLDLc) 
release from the liver in response to hyperinsulinemia. In lipodytrophic conditions the 
partially functioning insulin signalling pathway fails to fully suppress glucose 
production but does appear to induce DNL(28). DNL is probably only part of the 
pathogenesis of NAFLD in this setting with increased non-esterified fatty acid delivery 
to the liver another likely contributor(29). In contrast, insulin receptoropathies do not 
manifest increased DNL (Figure 1)(28) . 
 
2. Adiponectin is an adipokine produced exclusively by adipocytes. Although its function 
is not entirely clear circulating concentrations correlate with insulin sensitivity in most 
settings. When measured in lipodystrophic patients circulating adiponectin is low, 
whereas individuals with insulin receptoropathies have surprisingly normal or even 
elevated adiponectin concentrations(30). The implication being that adiponectin 
production by adipocytes is suppressed by the hyperinsulinemia of lipodystrophy and 
that a functioning insulin receptor is important to this activity. The observation that 
post insulin receptor signalling defects in AKT2 are associated with lower adiponectin 
levels  similar to those in lipodystrophy suggests that a post-receptor process is 
involved(28). Adipose specific INSR knockout mice also manifest elevated adiponectin 
levels(31).  
 
• Complex syndromes of insulin resistance 
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A number of complex syndromes have been described in which severe IR is a characteristic 
feature. The mechanism of IR in these disorders has often not been well characterised but 
there some intriguing mechanistic ‘threads’ eg. ciliary body function(32) and DNA repair 
mechanisms(33, 34). Although lipodystrophy and IR have been reported in a number of 
syndromes, adipose tissue loss is not a universal feature.  
  
 
Recent highlights 
 
• Common genetic variation is associated with adipose expandability  
 
Genome-wide association studies have identified common variants implicated in many 
diseases. Beyond monogenic disorders of severe IR the most common presentation of IR is in 
individuals with increasing BMI and this is a major factor in the pathogenesis of type 2 
diabetes mellitus(T2DM), yet the vast majority of genetic loci implicated in the pathogenesis 
of T2DM influence insulin secretion(35, 36). 
 
Untangling the genetic loci associated with IR at a population level was greatly enhanced by 
using fasting insulin as the primary phenotype and then adjusting for BMI. Strikingly, several 
genomic regions associated with IR based on fasting insulin and adjusted for BMI correlated 
with lower HDL and increased TG levels(37, 38). Further, Scott et al noted that these alleles 
were associated with a  lower BMI, total body fat, hip circumference and gynoid and leg fat 
based on DEXA fat mass quantification(39). More recently Lotta et al reported that SNPs in 
53 distinct genomic regions were  associated with increased fasting insulin(adjusted for BMI), 
higher TG and lower HDLc levels. A SNP score generated using the lead SNP in each of the 53 
genomic regions was used to evaluate the strength of association between these loci and IR. 
Enrichment for the SNP score was associated significantly with lower insulin sensitivity as 
measured by hyperinsulinemic euglycemic clamps and frequently sampled oral glucose 
tolerance test, considered gold standard measurements of insulin sensitivity. The 53-SNP 
genetic score was also significantly associated with lower levels of leg and gynoid fat, and 
consequently with increased type 2 diabetes mellitus and coronary heart disease risk. 
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Amongst a cohort of individuals who gained weight, those enriched for the SNP score were 
less likely to deposit fat in the gluteofemoral region(40). These observations suggest that 
enrichment for SNPs in IR loci is linked to reduced peripheral or hip adipose expandability, 
not dissimilar to the observations made in partial lipodystrophies. Individuals with FPLD1, a 
more prevalent partial lipodystrophy subtype are significantly enriched for the SNP score, 
suggesting a polygenic inheritance(40). The pattern of association observed in these studies 
strongly suggests that subtle differences in adipose tissue expandability contribute to IR in 
the general population, providing compelling human genetic support for the lipid overflow or 
expandability hypothesis. 
 
• Multiple Symmetric Lipomatosis  
 
Phenotype-genotype correlation in rare disease continues to offer a rewarding approach in 
the study of human biology. Multiple Symmetric Lipomatosis (MSL) is a condition of abnormal 
adipose tissue distribution first described in the 1800’s(41). Although the phenotype is 
heterogeneous it frequently presents with symmetrical fat accumulation in the upper back, 
neck and face. Metabolic complications (including insulin resistance, type 2 diabetes, 
dyslipidemia and NAFLD), peripheral and autonomic neuropathies are variably present (42). 
Early suggestions that defective mitochondrial function may be implicated in the 
pathogenesis of the condition emerged following observations of the association of MSL with 
myoclonus epilepsy and red ragged fibres (MERRF) a condition known to be caused by a 
mitochondrial DNA mutation(43).  Recently, whole exome sequencing identified Mitofusin 2 
(MFN2) as a candidate gene in three individuals with severe upper body symmetric 
lipomatosis, lower limb lipodystrophy and charcot marie tooth (CMT) axonal neuropathy(44). 
Another study describing three more affected patients affirmed these findings and the 
presence of a very specific missense mutation in at least one affected allele, namely the MFN2 
p.R707W mutation(45). All cases described to date have either been homozygous for this 
variant or carried it alongside a second null allele. Mutations in other regions of the gene are 
strongly linked to CMT2a without lipodystrophy(45). Mitofusin 2 is a GTPase localised to the 
mitochondrial membrane and plays a critical role in the process of mitochondrial fusion 
through the formation of homotypic and heterotypic dimers with a similar GTPase Mitofusin 
1(46). Individuals with MFN2 mutations have low leptin levels despite relatively normal 
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adipocyte morphology(44, 47). The expanded adipose depots are due to unilocular adipocyte 
hyperplasia and negative for brown adipose tissue markers such as UCP1. Electron 
microscopy revealed abnormal mitochondria in adipose samples from affected patients and 
mRNA analysis highlighted a mitochondrial stress response in keeping with elevated 
circulating lactate levels(47). Interestingly the lowest levels of leptin expression were 
observed among patients with the most severe adipose phenotype(47). Leptin is widely 
acknowledged as a signal of adipose energy stores which increases and decreases with 
changes in fat mass, though exactly how each adipocyte regulates leptin synthesis and 
secretion remains unclear. Total leptin deficiency is rare but has a striking phenotype of 
extreme hyperphagia and hypothalamic dysfunction and it has been observed in patients (and 
mice) with mutations of the leptin gene and in generalised lipodystrophies where a paucity 
of functional adipose tissue accounts for the lack of leptin. In MFN2 associated MSL,  we have 
a condition associated with mitochondrial dysfunction in hyperplastic adipose tissue 
associated with very low leptin levels suggesting that mitochondrial function is an important 
determinant of leptin gene expression.  
 
• Insights into insulin receptor signalling  
 
A consistent feature of the INSR mutation phenotype is normal or elevated adiponectin and 
an absence of dyslipidaemia and NAFLD. PI3 kinases are intracellular enzymes regulating 
membrane phosphoinositide phosphorylation immediately downstream of the INSR and 
insulin receptor substrate (IRS) proteins, and have long been considered as prime candidates 
for monogenic IR. They are composed of distinct regulatory and catalytic subunits encoded 
for by different genes forming heterodimers and mediating intracellular signalling. There have 
been a number of PI3Kinase subclasses identified sharing homology in the catalytic subunit 
but differing in their regulatory elements. Class 1A regulatory subunits are encoded by 3 
different genes PI3KR1, PI3KR2 and PI3KR3(48). SHORT syndrome is a rare condition 
characterised by the presence of short stature, hyper flexibility, ocular depression, a 
developmental defect of the iris and an abnormality in teething, it is accompanied by partial 
lipodystrophy and IR. It was recently shown to arise from loss-of-function mutations in the 
PIK3R1 gene encoding the p85alpha regulatory subunit(49-51).  The detailed study of 
individuals with SHORT syndrome arising due to heterozygous nonsense or missense 
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mutations in PIK3R1  confirmed severe IR in affected cases without dyslipidaemia or fatty 
liver, and in all but one with significantly elevated adiponectin levels(52). These observations 
suggest that proximal insulin signalling defects are associated with preserved adiponectin 
expression rather than defects exclusive to the insulin receptor.  
 
• Tissue-specific IR  
 
It is noteworthy that not all defects in insulin signalling have an equal impact on liver and 
muscle. Dash et al described a family with a primary defect in a RAB-GAP protein that 
regulates the trafficking of GLUT4 to the cell surface, this resulted in severe post-prandial IR 
in the face of normal fasting glucose and insulin levels (largely determined by hepatic 
responses to insulin; which do not involve GLUT4)(53). Moltke et al have shown that a 
mutation in a muscle-specific isoform of the same gene is highly prevalent in Greenland Inuit 
populations where it results in selective post-prandial hyperinsulinemia and 
hyperglycemia(54). 
 
• Conclusions 
 
We have reviewed rare disorders of adipose tissue and primary insulin signalling defects 
causing severe IR emphasizing instances where the identification and study of affected 
individuals has yielded significant insights into the consequences of adipose dysfunction, as 
well as the relevance of this paradigm to prevalent forms of IR, and/or the complexities of 
insulin signalling. As is the case with MFN2 mutations, monogenic disorders continue to pose 
challenging scientific questions and efforts continue to untangle the molecular biology of such 
conditions. 
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Table 1: Syndromes of Severe Insulin Resistance 
Gene Gene product and function Phenotype Ref 
Generalised Lipodystrophies 
Congenital 
AGPAT2 
1-acylglycerol-3phosphate O-acyltransferase 2; ER protein 
regulating triglyceride biosynthesis Generalised Lipoatrophy from birth, severe IR, dyslipidaemia, 
NAFLD, low leptin and adiponectin. 
(15, 16, 55, 
56) 
BSCL2 Seipin; ER protein involved in lipid droplet biogenesis 
CAV1 Caveolin-1; involved in formation of membrane caveolae  As above plus short stature  (57) 
PTRF 
Polymerase 1 and transcript release factor; localises to caveolae 
regulating formation and stability 
Generalised lipoatrophy and muscular dystrophy with milder 
metabolic phenotype. 
(58) 
Acquired 
Idiopathic/Radiotherapy/Drug-
related/ autoimmune 
NA Generalised lipoatrophy, IR (22) 
Partial Lipodystrophies 
Familial 
FPLD1 NA; likely polygenic in many cases 
Peripheral lipoatrophy, prominent abdominal adiposity, IR. Low 
adiponectin 
(59) 
LMNA  Lamin A/C; Nuclear envelope protein 
Limb, gluteofemoral and truncal subcutaneous fat loss, IR. 
Sparing adipose tissue at the neck and face, low adiponectin. 
(59, 60) 
PPARG 
Peroxisome proliferator activated receptor gamma; Nuclear 
transcription factor regulating adipocyte differentiation and 
function 
Peripheral lipoatrophy prominent, variable abdominal adiposity, 
hypertension, hypertriglyceridemia, low adiponectin 
(19, 20) 
PLIN1 
Perilipin 1; Lipid droplet coat protein involved in the regulation 
of lipolysis 
Limb and gluteofemoral fat loss, IR. (61) 
CIDEC 
Cell death inducing DFFA like effector C; required for unilocular 
lipid droplet formation in adipocytes 
Peripheral lipoatrophy with some multilocular adipocytes  (62) 
AKT2 
Akt serine/threonine kinase 2; key proximal insulin signalling 
intermediate 
IR, Dyslipidaemia and fatty liver, low adiponectin, lipodystrophy (63) 
PCYT1A 
Phosphate cytidylyltransferase 1, choline, alpha; involved in 
phosphatidylcholine synthesis 
Lipoatrophy, IR, low adiponectin, short stature. (64) 
Acquired 
Autoimmune NA 
Cephalocaudal lipoatrophy, minimal metabolic phenotype, Low 
C3, MPGN +/- other autoimmune disease 
(21, 22) 
HIV/ARV associated NA 
Progressive thinning of subcutaneous adipose tissue in the face, 
arms and legs. Increased truncal and abdominal adiposity may 
also be present 
 
Insulin Receptoropathies 
Complete/Proximal 
INSR  Insulin receptor; Tyrosine Kinase receptor for insulin  
Severe IR without dyslipidaemia or NAFLD, normal or high 
adiponectin, SHBG, IGF1 
(65) 
Anti-insulin receptor Antibodies NA IR, normal or high Adiponectin +/-Autoimmune disease. (27, 66) 
Partial/Distal  
AKT2  See above See above  
TBC1D4 
TBC domain family member 4; Rab-GTPase activating protein, 
regulates insulin dependent trafficking of GLUT4 
Post prandial IR (53) 
Complex Syndromes 
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POLD1  DNA Polymerase delta 1 
Mandibulo hypoplasia, deafness, progeria, lipodystrophy (MDLP 
syndrome) 
(33, 67) 
PIK3R1  
Phosphoinositide-3-kinase 85alpha regulatory subunit; key 
insulin signalling intermediate 
Short stature, hyper extensibility, ocular depression, rieger 
anomaly, teething delay (SHORT syndrome) 
(49, 50) 
WRN Werner syndrome RecQ like helicase; DNA helicase  Lipodystrophy, premature aging (Werner syndrome) (34, 68) 
ALMS1 
Alms1, centrosome and basal body associated protein involved 
in microtubule/ciliary function 
Rod-cone dystrophy, hepatic and renal dysfunction, deafness, IR 
(Alstrom’s syndrome) 
(32, 69) 
BLM Bloom syndrome RecQ like helicase; DNA helicase  
Lipodystrophy, Short stature, telangiectasia, IR (Bloom’s 
syndrome) 
(70) 
ZMPSTE24 (AND LMNA) 
Zinc metallopeptidase STE24; regulates posttranslational 
cleavage of prelamin  
Mandibuloacral dysplasia, Lipodystrophy, IR (71) 
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Figure 1: Monogenic disorders of insulin receptor signalling as a model for the uncoupling 
of insulin’s metabolic actions. 
Insulin binds to its transmembrane receptor activating a downstream signalling cascade 
regulating the hormone’s metabolic functions to increase glucose transport into the cell and 
consequently glycogen and lipid synthesis while suppressing hepatic glucose production. 
Defects (red shading) affecting the insulin receptor (INSR; Type A insulin resistance, Donohue 
and Rabson-Mendenhall syndromes), PI3Kinase p85alpha catalytic subunit (SHORT 
syndrome) and AKT2 lead to an uncoupling of insulin’s glucose lowering effects from SREPB1c 
regulated de novo lipogenesis. IRS, insulin receptor substrate; PIP2/3, phosphatidylinositol-
(4,5)-bisphosphate 2/3; mTOR1, mammalian target of rapamycin complex 1; SREBP1c, sterol 
regulatory element binding protein 1; FOXO1, forkhead box protein O1 and GSK3, glycogen 
synthase kinase 3. 
 
